The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions

Background: Chronic hepatitis C virus (HCV) infection causes a substantial health and economic burden in the United States. With the availability of direct-acting antiviral agents, recently approved therapies and those under development, and 1-time birth-cohort screening, the burden of this disease is expected to decrease. Objective: To predict the effect of new therapies and screening on chronic HCV infection and associated disease outcomes. Design: Individual-level state-transition model. Setting: Existing and anticipated therapies and screening for HC